Cawachi (TSE:2664) Stock Richens As Q2 Results Expose Margin Squeeze

Cawachi came into this earnings print with a rich 30.4x P/E and a stock that had climbed 22.4% over the past three months to ¥4,070, so expectations were already loaded. Q2 2027 results landed with basic earnings per share of ¥51.48 and net income of ¥1,143m, figures that look solid on the surface but sit against a thinner 1.1% net margin over the past year compared with 1.6% a year earlier. The market reaction has been brisk; however, the real story is the ongoing squeeze in profitability that now frames every move in the share price.

Like the Cawachi story but uneasy about that thin 1.1% net margin and premium 30.4x P/E? Set a higher bar with our list of solid balance sheet and fundamentals stocks (23 results) .

Q2 2027 Earnings Summary

• Revenue (Q2 2027 vs Q2 2026):¥72,162m vs. ¥74,332m (down 2.9%)

• Net Income (Q2 2027 vs Q2 2026):¥1,143m vs. ¥1,412m (down 19.1%)

• Basic EPS (Q2 2027 vs Q2 2026):¥51.48 vs. ¥63.22 (down 18.6%)

• Trailing 12M Net Income Margin (Q2 2027 vs prior year):1.1% vs. 1.6% (compression of 0.5 percentage points)

Earnings tell part of the story, but investors who care about what they are actually paying for tend to focus just as much on the cash coming in and out of a business. Looking at Cawachi's cash flows alone, the stock could be a solid 17% undervalued .

Cawachi's Defensive Story Meets Softer Earnings

Cawachi is often viewed as a steady, healthcare-linked retailer, and the latest numbers still lean in that direction on the demand side. Revenue of ¥72,162m in Q2 2027 stays close to the prior ¥74,332m, which fits a defensive consumption story rather than a boom or bust profile. Recent share price gains over 30 and 90 days also suggest investors have not abandoned that view. For a bullish stance, the appeal now rests more on perceived stability of everyday sales rather than on any clear acceleration in profitability.

Profit Squeeze Keeps Bearish Concerns In Play

The margin picture gives the cautious narrative real weight. Net income fell from ¥1,412m to ¥1,143m while the trailing 12‑month net margin compressed from 1.6% to 1.1%. That signals a tighter profit pool supporting the same store-heavy model. In a crowded Japanese drugstore market, this thinner cushion reinforces worries about pricing pressure and cost inflation. The business still generates earnings, but the direction of profitability suggests limited room for error if competition intensifies or operating expenses rise further.

After a period of thinner profitability and large one off items in the accounts, it is fair to ask whether Cawachi's earnings risk is fully visible from headline numbers alone. Review the full risk analysis for Cawachi which shows 4 important warning signs